Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 2 de 2
Filter
Add more filters










Database
Language
Publication year range
1.
Ir J Med Sci ; 187(2): 417-421, 2018 May.
Article in English | MEDLINE | ID: mdl-28988372

ABSTRACT

AIM: We aimed to investigate the effectivity of the 0.0625 mg dose of bevacizumab in patients with retinopathy of prematurity (ROP) and compare the results with 0.625 mg dose of intravitreal bevacizumab (IVB) injection. METHODS: The medical records of the patients with type 1 ROP who received IVB monotherapy were retrospectively reviewed. Demographic and clinical characteristics of the patients were recorded. The patients were classified into two groups with respect to received dose of bevacizumab as follows: group F (n = 46) (full dose of bevacizumab-0.625 mg/0.025 ml) and group L (n = 45) (low dose (one tenth) of bevacizumab-0.0625 mg/0.025 ml). RESULTS: Both treatment dose regimens have similar outcomes. Moreover, the mean retinal vascularization time seemed to be significantly higher in group F compared to group L, 168 ± 65 and 97 ± 29 days, respectively (p < 0.001). Disappearance of plus sign is observed earlier in group F (2.45 ± 1.7 vs 3.66 ± 2.46 days, respectively, p = 0.03). CONCLUSIONS: The low dose (0.0625 mg) of IVB treatment was effective as full (0.625 mg) dose in ROP treatment. Moreover, our results showed that low-dose treatment might provide faster retinal vascularization than the regular used dose. On the other hand, disappearance of the plus sign takes longer time in patients treated with low dose compared to eyes treated with full dose of IVB that should be taken into account.


Subject(s)
Antineoplastic Agents, Immunological/therapeutic use , Bevacizumab/therapeutic use , Intravitreal Injections/methods , Retinopathy of Prematurity/drug therapy , Antineoplastic Agents, Immunological/administration & dosage , Antineoplastic Agents, Immunological/pharmacology , Bevacizumab/administration & dosage , Bevacizumab/pharmacology , Female , Humans , Infant, Newborn , Male , Retinopathy of Prematurity/pathology , Retrospective Studies
2.
Clin Exp Dermatol ; 40(5): 507-12, 2015 Jul.
Article in English | MEDLINE | ID: mdl-25754533

ABSTRACT

AIM: To evaluate the blood flow in arteries of the orbit in patients with psoriasis. METHODS: In total, 30 patients with psoriasis and 30 healthy control subjects were recruited to the study. Standard ophthalmic evaluation, fundus examination and retrobulbar colour Doppler ultrasonography assessment were performed. The ophthalmic, posterior ciliary and central arteries were evaluated, and peak systolic blood flow velocity, end diastolic velocity, resistance index and pulsatility index were measured. Results of the measurements were compared between the two study groups. RESULTS: There were significant differences in blood flow parameters of the orbital arteries between the psoriasis group and the control group. CONCLUSIONS: The haemodynamics of the orbit might be affected in patients with psoriasis.


Subject(s)
Eye/blood supply , Psoriasis/physiopathology , Adolescent , Adult , Case-Control Studies , Ciliary Arteries/diagnostic imaging , Ciliary Arteries/physiopathology , Eye/diagnostic imaging , Female , Hemodynamics/physiology , Humans , Male , Ophthalmic Artery/diagnostic imaging , Ophthalmic Artery/physiopathology , Psoriasis/diagnostic imaging , Regional Blood Flow/physiology , Retinal Artery/diagnostic imaging , Retinal Artery/physiopathology , Ultrasonography, Doppler, Color , Young Adult
SELECTION OF CITATIONS
SEARCH DETAIL
...